Could a single infusion of 'Trainer' cells free liver transplant patients from lifelong drugs?

NCT ID NCT04208919

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study tests whether a single infusion of donor-derived regulatory dendritic cells (DCreg) can help living donor liver transplant recipients safely stop taking immunosuppression drugs. Participants are low-risk patients who are 1 to 3 years post-transplant. They receive the DCreg infusion and then slowly wean off their anti-rejection medication, with close monitoring for rejection and other complications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
donor-derived regulatory dendritic cells (DCreg)
What this could lead to
If successful, this approach could allow liver transplant recipients to stop taking lifelong immunosuppression drugs without rejecting the new liver.
What could go wrong
This is an early-phase trial with only 16 participants, so results may not apply broadly. There are risks of severe infusion reactions, infections, rejection, or graft loss.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END STAGE LIVER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • UPMC

    Pittsburgh, Pennsylvania, 15213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.